Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral

Journal of Heart and Lung Transplantation

Volumn 31, Issue 4, 2012, Pages 364-372

  Badagliacca, Roberto ^a   Pezzuto, Beatrice ^a   Poscia, Roberto ^a   Mancone, Massimo ^a   Papa, Silvia ^a   Marcon, Serena ^a   Valli, Gabriele ^a   Sardella, Gennaro ^a   Ferrante, Fabio ^a   Iacoboni, Carlo ^a   Parola, Daniela ^a   Fedele, Francesco ^a   Vizza, Carmine Dario ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

epoprostenol; prostanoids; pulmonary arterial hypertension; survival; treprostinil

Indexed keywords

PROSTACYCLIN; PROSTANOID; UNIPROST;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; HAZARD RATIO; HEART INDEX; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL SOCIETY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SURVIVOR;

ADULT; AGED; EPOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROSTAGLANDINS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84858337130     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2011.12.011     Document Type: Article

References (28)

1. G. Simonneau, N. Gali, L.J. Rubin Clinical classification of pulmonary hypertension J Am Coll Cardiol 43 12 Suppl S 2004 5 12S
2. G.E. D'Alonzo, R.J. Barst, S.M. Ayres Survival in patients with primary pulmonary hypertension Results from a national prospective registry Ann Intern Med 115 1991 343 349
3. T. Higenbottam, D. Wheeldon, F. Wells, J. Wallwork Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin) Lancet 1 1984 1046 1047 (Pubitemid 14148935)
4. L.J. Rubin, J. Mendoza, M. Hood Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol) Results of a randomized trial Ann Intern Med 112 1990 485 491 (Pubitemid 20100285)
5. R.J. Barst, L.J. Rubin, W.A. Long et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension The Primary Pulmonary Hypertension Study Group N Engl J Med 334 1996 296 302
6. V.V. McLaughlin, S.P. Gaine, R.J. Barst Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension J Cardiovasc Pharmacol 41 2003 293 299 (Pubitemid 36135255)
7. H. Olschewski, G. Simonneau, N. Galie Aerosolized Iloprost Randomized Study Group Inhaled iloprost for severe pulmonary hypertension N Engl J Med 347 2002 322 329 (Pubitemid 34815354)
8. L.J. Rubin, D.B. Badesch, R.J. Barst Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 2002 896 903 (Pubitemid 34984638)
9. R.J. Barst, D. Langleben, A. Frost Sitaxsentan therapy for pulmonary arterial hypertension Am J Respir Crit Care Med 169 2004 441 447 (Pubitemid 38187114)
10. N. Gali, H. Olschewski, R.J. Oudiz Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 Circulation 117 2008 3010 3019
11. N. Gali, H.A. Ghofrani, A. Torbicki Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2002 2148 2157
12. N. Galie', B.H. Brundage, H.A. Ghofrani Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group Tadalafil therapy for pulmonary arterial hypertension Circulation 119 2009 2894 2903
13. V.V. Mc Laughlin, O. Sitbon, D.B. Badesh Survival with first-line bosentan in patients with primary pulmonary hypertension Eur Respir J 25 2005 244 249 (Pubitemid 40246523)
14. S. Provencher, O. Sitbon, M. Humbert, S. Cabrol, X. Jais, G. Simonneau Long term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension Eur Heart J 27 2006 589 595
15. R.L. Benza, R.J. Barst, N. Gali Sitaxsentan for the treatment of pulmonary arterial hypertension A 1-year, open-label observation of outcome and survival Chest 133 2008 775 782
16. L.J. Rubin, B. Badesch, T. Fleming Long-Term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension Chest 140 2011 1274 1283
17. N. Gali, M.M. Hoeper, M. Humbert Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
18. R.L. Benza, D.P. Miller, M. Gomberg-Maitland Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) Circulation 122 2010 164 172
19. R.J. Barst, L.J. Rubin, M.D. McGoon Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin Ann Intern Med 121 1994 409 415
20. V.V. McLaughlin, A. Shillington, S. Rich Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 2002 1477 1482
21. O. Sitbon, M. Humbert, H. Nunes Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788 (Pubitemid 34925627)
22. K.P. Kuhn, D.W. Byrne, P.G. Arbogast, T.P. Doyle, J.E. Loyd, I.M. Robbins Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol Am J Respir Crit Care Med 167 2003 580 586
23. R.J. Barst, N. Galie, R. Naeije Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Eur Respir J 28 2006 1195 1203 (Pubitemid 44883856)
24. I. Lang, M. Gomez-Sanchez, M. Kneussl Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension Chest 129 2006 1636 1643 (Pubitemid 43894997)
25. O. Sitbon, V.V. McLaughlin, D.B. Badesch Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol Thorax 60 2005 1025 1030 (Pubitemid 41705471)
26. M. Humbert, O. Sitbon, A. Yaci Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension Eur Respir J 36 2010 549 555
27. Tankersley MA, D'Albini LD, Ozanich AN, Whitman AJ. A 36 month survival analysis of patients beginning oral PAH monotherapy: an indication for escalation of therapy? Poster 1062. Presented at Pulmonary Hypertension Association Meeting, Houston, Texas, June 20-22, 2008.
28. R.J. Barst, J.S. Gibbs, H.A. Ghofrani Updated evidence-based treatment algorithm in pulmonary arterial hypertension J Am Coll Cardiol 54 1 Suppl 2009 S78 S84